REFERENCIAS

1. Mueller NH, Gilden DH, Cohrs RJ, et al. Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease and Latency. Neurologic Clinics. 2008 Nov;26(4):675-97.

2. Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013 Apr;14(2):77-85.

3. Saibara T, Maeda T, Onishi S, et al. Depressed immune functions in the early phase of varicella-zoster virus reactivation. J Med Virol. 1993 Mar;39(3):242-5.

4. Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013 Sep;125(5):78-91.

5. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of Herpes Zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 Mar 28;57(RR-5):1-30.

6. Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Herpes zoster risk and burden of disease in immunocompromised populations: a population - based study using health system integrated databases, 2009-2014. BMC Infect Dis. 2020;20(1):905.